Ukuba uthabatha i-hormone ye-hormone esikhundleni se-Synthroid, unokuva malunga nokugwetywa kwezenzo zetekisi ezifakwe kumenzi weziyobisi ze-Knoll Pharmaceuticals, kunye nenkampani yabazali be-BASF, ngasekupheleni kweminyaka yama-1990. Lezo zigwebo ziye zazinziswa, kodwa kubalulekile ukwazi ngalo, njengenxalenye yembali yale nkunkuma ebizwa nge-levothyroxine.
Eminye Imbali
Ngama-1990, i-Synthroid yenziwe yi-Knoll Pharmaceuticals. I-Synthroid yayineengxelo ezingama-85 zeemakethe ze-levothyroxine ngo-1997. I-Synthroid yayihlala ixabiso eliphezulu ngaphezu kwamashishini alo, kunye nabathengisi bezonyango kunye neentengiso zokubhengeza bathi ixabiso eliphezulu lifanelekile njengoko le nkunkuma yayingcono kunezokhuphiswano. Inkampani iboniswe ukubonakalisa oku ngophando kwaye yathumela isifundo ukuba ibonise ukuba i-Synthroid yayinempilo ekliniki engcono kunezinye izibizo kunye negama le-levothyroxine.
Uphononongo olwenziwa nguBetty Dong, MD, lufumene ukuba i-Synthroid ilingana, kodwa ingaphelelanga, ukusetyenziswa kweziyobisi ze-levothyroxine. Ngelo xesha, uKnoll wadonsa isifundo kwaye wayenqanda ukupapashwa kweziphumo kumaphephancwadi ezonyango. Ngenxa yezichaso zikaKnoll, uDkt. Dong ekugqibeleni wayenalo uphando olupapashwe.
Emva kokupapashwa koPhando lukaDkt Dong, izigwebo zentsebenzo yeklasi zafakwa egameni labathengi ababekholelwa ukuba bakhohliswa ukuhlawula i-Synthroid.
Isenzo seklasi sazinziswa ngo-2000, kwaye iintlawulo zokugqibela kwabathengi zenziwe ngo-2003. (Qaphela: Abathengi abangakhange bafake ngelo xesha abanakufumana imali.)
Isiseko seNkundla yokuLawulwa kweCandelo
Icala laphumela ekuphenyweni, okwaqala ngowama-1996, oku kuthiwa i-Knoll Pharmaceuticals kunye nenkampani yomzali iBASF yayiphulaphula imithetho yokukhusela abathengi ngokuzama ukukhusela ukupapashwa kweziphumo zoPhando lukaDkt. Dong, olubonisa ngokucacileyo ukuba igama lomenzi izidakamizwa ze-levothyroxine zazilingana ne-Synthroid brand ngokubhekiselele ekusebenzeni nasekukhuseleni izigulane ze-thyroid.
UDkt. Dong utshele i- Journal ye-American Medical Association ukuba isifundo sagxothwe iminyaka emithandathu yinkampani yeziyobisi. U-Knoll wayeye wacinga ukukhangela ukushicilelwa ukuyeka ukupapashwa kwesifundo.
I-suit iyaxela ukuba abachasayo bafihliwe okanye baxinekile ngolwazi ngegama elinguxabiso elingu-bioequivalent kunye ne-generic levothyroxine iziyobisi, babemela ngamanga ukuba akukho zilinganiso kwi- Synthroid , kwaye ngoko ke abathengisa abathengi ngaphezu kokuba babeza kuchitha ukuba babesazi ukuba zibiza ezinye iindlela.
I-Synthroid Class Action Actsuit Settlement
Izibophelo zokuqala malunga noKnoll zazingabaluleka ukuya kuma-8.5 billion. Ngelo xesha ngo-2000, imarike ye-levothyroxine yayiqikelelwa kwiizigidi ezingama-600 ngonyaka. Noko ke, ukuhlaliswa, okwenziwe kwithuba elincinci kunabamangali abafunayo.
NgoLwesibini, ngo-Agasti 8, 2000, iNkampani yeMachiza i-Knoll yamemezela ukuba uMgwebi u-Elaine Bucklo weNkundla yeSithili sase-US kwiNgingqi yaseMntla yase-Illinois wanikezela imvume yokugqibela yokulungiswa komthetho we-Synthroid.
Imali evela kwi-akhawunti ye-escrow, efana neye-Juni 30, 2000, equle i-$ 91 yezigidi kunye nomdla (iindleko zabameli bambalwa kunye neendleko) zonyulwe ukuba zihlawulwe kubathengi abafake njengenxalenye yomgwebo kwaye bavuma ukukhulula onke amabango malunga noKnoll.
Isixa esimalunga neerandi ezingama-46 kunye nomdla (iindleko zommeli ezimbalwa kunye neendleko) kwakufuneka zihlawulwe kumalungu eklasi ehlawula umvuzo wesithathu.
Ngelo xesha, uKololl waqikelela ukuba abathengi abangama-778,000 baya kufumana iintlawulo ezimalunga ne-$ 111 nganye xa beqala ukuthatha i-Synthroid ngaphambi koJanuwari 1, 1995, kunye ne-$ 74 nganye xa beqala ukuthatha i-Synthroid emva koJanuwari 1, 1995. iintlawulo zafuneka zithunyelwe ngaphambi kokuba ekupheleni kuka-2000 ukuba akukho zibheno ezifakiwe. Izibheno zafakwa, nangona kunjalo, kwaye iindawo zokuhlala zakhawuleza.
Ekugqibeleni, ukuhlolwa kwagqitywa kwithunyelwa kwizigulane ekuwa kwe-2003. Ngelo xesha, iwebhusayithi ezinikele ekunikezeni ulwazi malunga necala kunye nokuhlaliswa kwayo yachithwa kwaye yacinywa.
ILizwi
Umgwebo malunga nomenzi we-Synthroid we-Knoll Pharmaceuticals kunye nenkampani yabazali be-BASF ayizange ibe yikho ukhuseleko okanye ukuphumelela kwe-Synthroid. Esi sigxina sasisoloko sithathwa siphephile kwaye sisebenza. Icala lijongene neengxaki zokuthengisa ukuba i-Synthroid-brand levothyroxine yayiphezulu kunezinye iimveliso ze-levothyroxine, kunye nenyaniso yokuba inkampani ihlawulise ngakumbi i-Synthroid ngokusekelwe kuloo mgaqo.